Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

lohmann & rauscher pty ltd - 62978 - padded stays splint, single-use, non-sterile - this non-sterile padded device is intended to be used for the immobilisation and protection of injured body parts.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

tauropharm australia pty ltd - 57875 - non-antibiotic-based antimicrobial catheter lock solution - to be instilled into the lumens of a port or catheter-based vascular access device between patient treatments in order to inhibit blood clot formation and pathogenic microbial (bacterial/fungal) growth and maintain the patency of the vascular access device. the solution is intended to be instilled at the termination of a treatment and withdrawn prior to subsequent treatment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medical specialties australasia pty ltd - 57875 - non-antibiotic-based antimicrobial catheter lock solution - maintain patency and decrease the risk of bacterial colonization and biofilm formation within central venous access devices (cvad)

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxytocin 10 iu/ml (added as 200 iu/ml solution.);   - solution for injection - 10 iu/ml - active: oxytocin 10 iu/ml (added as 200 iu/ml solution.)   excipient: acetic acid chlorobutanol ethanol sodium acetate trihydrate water for injection - antepartum: · induction of labour for medical reasons, e.g. in cases of post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia). · enhancement of labour in selected cases of uterine inertia. · syntocinon may also be indicated in early stage of pregnancy, as adjunctive therapy for management of incomplete, inevitable or missed abortion.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxytocin 5 iu/ml (added as 200 iu/ml solution.);   - solution for injection - 5 iu/ml - active: oxytocin 5 iu/ml (added as 200 iu/ml solution.)   excipient: acetic acid chlorobutanol ethanol sodium acetate trihydrate water for injection - antepartum: · induction of labour for medical reasons, e.g. in cases of post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia). · enhancement of labour in selected cases of uterine inertia. · syntocinon may also be indicated in early stage of pregnancy, as adjunctive therapy for management of incomplete, inevitable or missed abortion.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - pyridostigmine bromide 60mg equivalent to a 2% overage is added during manfuacuture;   - tablet - 60 mg - active: pyridostigmine bromide 60mg equivalent to a 2% overage is added during manfuacuture   excipient: colloidal silicon dioxide lactose stearic acid - myasthenia gravis; paralytic ileus; postoperative urinary retention.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 20 mg/ml (5% overage is added.) - oral suspension - 100 mg/5ml - active: rifampicin 20 mg/ml (5% overage is added.) excipient: agar diolamine methyl hydroxybenzoate polysorbate 80 potassium sorbate propyl hydroxybenzoate purified water raspberry saccharin sodium metabisulfite sucrose - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lorazepam 0.5mg (3% overage added) - tablet - 0.5 mg - active: lorazepam 0.5mg (3% overage added) excipient: indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose polacrilin potassium - ativan (lorazepam) is useful in the therapy of most disorders in which anxiety is a major component. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. treatment of moderate to severe anxiety.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: colloidal silicon dioxide magnesium stearate povidone pregelatinised maize starch - latest regulatory activity

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - enteric coated tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: carnauba wax cellacefate colloidal silicon dioxide macrogol 20000 magnesium stearate povidone propylene glycol purified talc self-emulsifying glyceryl monostearate starch white beeswax - ulcerative colitis and crohn's disease adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis salazopyrin en tablets are indicated for rheumatoid arthritis which has failed to respond to nonsteroidal anti-inflammatory drugs (nsaids).